Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

9.44
+0.61006.91%
Post-market: 9.520.0800+0.85%19:59 EDT
Volume:27.29M
Turnover:263.21M
Market Cap:10.00B
PE:-9.55
High:10.09
Open:8.92
Low:8.90
Close:8.83
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.87
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-9.56
PE(LYR):-24.71

Loading ...

Movement Alert|ImmunityBio Falls 5.01% in Regular Trading, Sustained Profit-Taking Pressure After Multiple Catalysts Realized

Market Focus
·
Jun 06

ImmunityBio (IBRX) Is Down 5.6% After New Phase 3 ANKTIVA Lung Cancer Data Release – Has The Bull Case Changed?

Simply Wall St.
·
Jun 05

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors

TIPRANKS
·
Jun 05

ImmunityBio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

ImmunityBio presents Phase 3 lung cancer data on ANKTIVA-based regimen at ASCO 2026

Reuters
·
Jun 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Movement Alert|ImmunityBio Falls 5.12% in Regular Trading, Technical Rebound Fades as Profit-Taking Resumes After Multiple Catalysts Priced In

Market Focus
·
May 29

How FDA Review of ANKTIVA Bladder Cancer sBLA Could Impact ImmunityBio (IBRX) Investors

Simply Wall St.
·
May 29

Movement Alert|ImmunityBio Rises 5.66% in Regular Trading, AUA Positive Efficacy Data Fuels Rebound After Two-Day Selloff

Market Focus
·
May 26

Movement Alert|ImmunityBio Falls 5.23% in Regular Trading, Profit-Taking Continues After Multiple Catalysts Priced In

Market Focus
·
May 22

ImmunityBio survey shows UK NMIBC patients favor bladder-sparing therapy after BCG failure

Reuters
·
May 22

ImmunityBio says ANKTIVA plus BCG shows lower cost per sustained responder vs TAR-200

Reuters
·
May 22

Is ANKTIVA’s BCG Tie-Up And New Patents Altering The Investment Case For ImmunityBio (IBRX)?

Simply Wall St.
·
May 21

Movement Alert|ImmunityBio Falls 7.89% in Regular Trading, Profit-Taking Emerges After Multiple Catalysts Priced In

Market Focus
·
May 21

ImmunityBio faces securities class action after FDA flags misleading Anktiva cancer claims

Reuters
·
May 21

Movement Alert|ImmunityBio Rises 5.03% in Regular Trading, Positive Clinical Data and Patent Grants Fuel Rally

Market Focus
·
May 21

Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury

Reuters
·
May 20

S&P 500 Futures Rise In Premarket Trading; Immunovant, ImmunityBio Lead

Dow Jones
·
May 20

ImmunityBio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
May 20

ImmunityBio's Supplemental Biologics License Application for Anktiva Accepted by FDA

MT Newswires Live
·
May 20